Revolutionary New Intranasal Vaccine Debuts In Market, Offering Enhanced Convenience And Protection | Health Live

Researcher Xiang Liu highlights that SARS-CoV-2 (COVID-19) continues to have a significant global health and economic impact. Although spike-protein vaccines are effective in preventing severe disease, they struggle with providing long-lasting protection against emerging variants, breakthrough infections, and transmission. To address this, Xiang Liu's team developed an intranasal live-attenuated SARS-CoV-2 vaccine, CDO-7N-1, using codon deoptimization. CDO-7N-1 exhibits highly attenuated replication with minimal lung pathology in vivo across multiple passages. It successfully induces strong mucosal and systemic neutralizing antibody and T-cell responses with just a single dose, as demonstrated in studies with mice (female K18-hACE2 and male HFH4-hACE2), hamsters, and macaques.